We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
- Authors
Lu, Jun; Zhang, Qi; Liang, Chun-Min; Xia, Shu-Jie; Zhong, Cui-Ping; Wang, Da-Wei
- Abstract
Aim: To investigate the antitumor immunity by a dendritic cell (DC) vaccine encoding secondary lymphoid chemokine gene and tumor lysate on murine prostate cancer. Methods: DC from bone marrow of C57BL/6 were transfected with a plasmid vector expressing secondary lymphoid chemokine (SLC) cDNA by Lipofectamine2000 liposome and tumor lysate. Total RNA extracted from SLC+lysate–DC was used to verify the expression of SLC by reverse transcriptase-polymerase chain reaction (RT-PCR). The immunotherapeutic effect of DC vaccine on murine prostate cancer was assessed. Results: We found that in the prostate tumor model of C57BL/6 mice, the adminstration of SLC+lysate–DC inhibited tumor growth most significantly when compared with SLC–DC, lysate–DC, DC or phosphate buffer solution (PBS) counterparts ( P < 0.01). Immunohistochemical fluorescent staining analysis showed the infiltration of more CD4+, CD8+ T cell and CD11c+ DC within established tumor treated by SLC +lysate–DC vaccine than other DC vaccines ( P < 0.01). Conclusion: DC vaccine encoding secondary lymphoid chemokine and tumor lysate can elicit significant antitumor immunity by infiltration of CD4+, CD8+ T cell and DC, which might provide a potential immunotherapy method for prostate cancer.
- Publication
Asian Journal of Andrology, 2008, Vol 10, Issue 6, p883
- ISSN
1008-682X
- Publication type
Article
- DOI
10.1111/j.1745-7262.2008.00431.x